Searchable abstracts of presentations at key conferences in endocrinology

ea0026p445 | Thyroid (non cancer) | ECE2011

Thyroid function and mortality in euthyroid subjects

Roos A , Links T P , Gans R O B , Wolffenbuttel B H R , Bakker S J L

Objective: Many studies suggest that thyroid function modifies the process of healthy aging in humans. However, both a progressive increase and decrease of TSH with advancing age have been reported. The discrepancy may lie in the iodine intake in the population under, since low iodine intake results in an inverse association of TSH with age, while high iodine intake results in a positive association. We aimed to investigate whether FT4, FT3 and FT3</...

ea0026p397 | Thyroid (non cancer) | ECE2011

Thyroid status and health-related quality of life in the LifeLines-cohort

Klaver E I , Stienstra R , van der Klauw M M , Kema I P , Wolffenbuttel B H R

Background: Thyroid disorders are prevalent in western society, yet many subjects experience limited symptoms at diagnosis, especially in hypothyroidism.Design: In order to compare the health-related quality of life (HR-QOL) of subjects with suppressed TSH-levels (TSH<0.5 mU/l) or elevated TSH-levels (TSH>10 mU/l) to subjects with normal TSH-levels (TSH 0.5–4 mU/l), a cross-sectional study was performed within the Dutch adult population who ...

ea0026p237 | Pituitary | ECE2011

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Postma M R , Netea-Maier R T , van den Berg G , Homan J , Sluiter W J , van den Bergh A C M , Wolffenbuttel B H R , Hermus A R M M , van Beek A P

Objective: To assess the influence of use of long-acting somatostatin analogs on long-term health-related quality of life (HR-QoL) in relation to disease control in patients surgically-treated for acromegaly.Design: Cross-sectional study in two University Medical Centers in The Netherlands.Patients: One hundred and eight patients (47 m/61 f, mean age 54±11 years) with a minimal follow up period of 1 year after pituitary surger...